

Forigerimod

Cat. No.:	HY-105037
CAS No.:	497156-60-2
Molecular Formula:	C ₁₁₇ H ₁₈₁ N ₃₄ O ₃₂ PS
Molecular Weight:	2638.94
Sequence:	Arg-Ile-His-Met-Val-Tyr-Ser-Lys-Arg-[pSer]-Gly-Lys-Pro-Arg-Gly-Tyr-Ala-Phe-Ile-Glu-Tyr
Sequence Shortening:	RIHMOVYSKR-[pSer]-GKPRGYAFIEY
Target:	Autophagy
Pathway:	Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Forigerimod (IPP-201101) is a CD4 T-cell modulator. Forigerimod is a 21-amino-acid fragment of U1 small nuclear ribonucleoprotein 70 kDa that is phosphorylated at Ser140. Forigerimod can potentially inhibit autophagy. Forigerimod can be used for the research of autoimmune disorders, such as systemic lupus erythematosus (SLE) [1][2][3][4].								
In Vivo	<p>Forigerimod (P140) (i.v.; 100 µg in 100 µL saline per mouse) directly acts on chaperone-mediated autophagy, rescues MRL/lpr mice from cellular infiltration and autophagy defects occurring in salivary glands^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table> <tr> <td>Animal Model:</td> <td>MRL/lpr mice^[4]</td> </tr> <tr> <td>Dosage:</td> <td>100 µg in 100 µL saline per mouse</td> </tr> <tr> <td>Administration:</td> <td>Intravenous administration, single</td> </tr> <tr> <td>Result:</td> <td>Corrected the cell content and distribution in MRL/lpr salivary glands. Corrected the defective of autophagy processes in SGs of MRL/lpr mice.</td> </tr> </table>	Animal Model:	MRL/lpr mice ^[4]	Dosage:	100 µg in 100 µL saline per mouse	Administration:	Intravenous administration, single	Result:	Corrected the cell content and distribution in MRL/lpr salivary glands. Corrected the defective of autophagy processes in SGs of MRL/lpr mice.
Animal Model:	MRL/lpr mice ^[4]								
Dosage:	100 µg in 100 µL saline per mouse								
Administration:	Intravenous administration, single								
Result:	Corrected the cell content and distribution in MRL/lpr salivary glands. Corrected the defective of autophagy processes in SGs of MRL/lpr mice.								

REFERENCES

- [1]. Aikaterini Thanou, et al. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys.
- [2]. Sean Robinson, et al. Potential for Antigen-Specific Tolerizing Immunotherapy in Systematic Lupus Erythematosus. *Front Immunol.* 2021 Jul 16;12:654701.
- [3]. Robert Zimmer, et al. Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial. *Ann Rheum Dis.* 2013 Nov;72(11):1830-5.
- [4]. Baihui Li, et al. Rescue of autophagy and lysosome defects in salivary glands of MRL/lpr mice by a therapeutic phosphopeptide. *J Autoimmun.* 2018 Jun;90:132-145.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA